VAC4EU Partners

Partner Updates July 2022

VAC4EU x SIGMA

We are pleased to announce that VAC4EU and the SIGMA Consortium have formally joined forces and expressed our shared vision and a mutual goal to continue collaborating, developing existing synergies, and sharing expertise and knowledge, information, and tools developed by the two networks for pharmacoepidemiology/real-world evidence studies and activities.
SIGMA Consortium is a contract-based alliance of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) research centers launched on 11th November 2011. It is being launched to enable multi-country studies using common analyses to study responses to treatments in large populations, and to clarify and quantify these treatment effects for the citizens of Europe.

VAC4EU x Global Vaccine Data Network™ (GVDN™)

The GVDN™, a multinational, investigator-led network, was founded in 2019 with 21 partner sites across 17 countries. They now have 23 partners across 19 countries, representing more than 250 million people, and continue to expand. They aim to: 

  • Evaluate vaccine safety concerns through analysis and evaluation of large clinical databases, focusing on rare events 

  • Evaluate vaccine effectiveness to facilitate risk/benefit analyses 

  • Coordinate response to concerns regarding vaccines, such as vaccine hesitancy 

VAC4EU is an active member of the GVDN™. We recently contributed to the latest newsletter of the GVDN™ entitled Safety by Numbers with an overview of the COVID-19 vaccine studies finished and the ongoing work in which VAC4EU coordinates or participates. 

GVDN™ Newsletter – ISSUE 1 – MAY 2022

VAC4EU x ACN

Active Citizenship Network (ACN) was initiated in December 2001 as the European and international interface of the Italian civic participation organization Cittadinanzattiva (Active Citizenship). ACN is a flexible network of European civic organizations which are involved as partners in its different projects, addressed to encourage active participation of citizens in European policy-making. 

At the beginning of 2022, a collaboration between VAC4EU and CAN was established. The 3 major objectives of a fair collaboration between the 2 organizations are: 

  • To explore common training activities and/or how to participate in each other’s training program 

  • To identify project calls to which both organizations could apply together, leveraging each other’s expertise 

  • To build trust and collaboration to increase access to information on vaccines with the scientifically independent support from VAC4EU and the citizens outreach from ACN